139 results
8-K
EX-99.1
ALIM
Alimera Sciences Inc.
7 Mar 24
Alimera Sciences Reports Fourth Quarter and Full Year 2023 Results
8:32am
recruitment in the Synchronicity Study for YUTIQ, which is a prospective, open-label clinical study evaluating the safety and efficacy of YUTIQ
8-K
EX-99.1
ALIM
Alimera Sciences Inc.
26 Oct 23
Alimera Sciences Reports Third Quarter 2023 Results
7:39am
the safety and efficacy of YUTIQ for the treatment of chronic, non-infectious uveitis affecting the posterior segment and related intraocular inflammation
8-K
EX-2.1
9jjbyysr
18 May 23
Expected to be immediately accretive to revenue and Adjusted EBITDA in 2023
4:55pm
8-K
EX-10.1
6xh53k
18 May 23
Expected to be immediately accretive to revenue and Adjusted EBITDA in 2023
4:55pm
8-K
EX-99.1
hid8xhhk79nlcixo90sb
31 Mar 23
Alimera Sciences Announces 2022 Financial Results and Business Update
8:43am
8-K
EX-10.4
ykk4iab83 sfr
14 Apr 21
Alimera Sciences receives $20 million
9:12am